Adrenal Cortical Carcinoma

Bladder Cancer

Kidney Cancer

Prostate Cancer

Testicular Cancer

Testicular Tumors

Urologic Cancers

Dr. Oh, Deputy Director, The Tisch Cancer Institute, Mt. Sinai Health System, elaborates on the scope of unmet need for patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) and how the treatment landscape is evolving

William Oh, MD, discusses the evolving treatment landscape for patients with nmCRPC

Dr. Oh, Deputy Director, The Tisch Cancer Institute, Mt. Sinai Health System, considers how prostate-specific antigen (PSA) is most valuable as a biomarker in the treatment of prostate cancer

William Oh, MD, tells us how PSA is valuable as a biomarker in the treatment of prostate cancer

William Oh, MD, Chief of the Division of Hematology and Medical Oncology and Associate Director for Clinical Research at The Tisch Cancer Institute, discusses his passion for research and prostate cancer.

Biography

Biography

Video

Video